The role of imaging in screening special feaTure: review arTicle whole Body mri and oncology: recent major advances
暂无分享,去创建一个
[1] Jef Vandemeulebroucke,et al. Registration strategies for multi‐modal whole‐body MRI mosaicing , 2018, Magnetic resonance in medicine.
[2] Thomas Wiegel,et al. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. , 2018, European urology.
[3] Y. Ohno,et al. Diagnostic performance of different imaging modalities in the assessment of distant metastasis and local recurrence of tumor in patients with non‐small cell lung cancer , 2017, Journal of magnetic resonance imaging : JMRI.
[4] David M. Thomas,et al. Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis , 2017, JAMA oncology.
[5] Simone Schrading,et al. Abbreviated Biparametric Prostate MR Imaging in Men with Elevated Prostate-specific Antigen. , 2017, Radiology.
[6] Caleb K. Stein,et al. Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. , 2017, Blood.
[7] Vicky Goh,et al. Guidelines for the use of imaging in the management of patients with myeloma , 2017, British journal of haematology.
[8] S. Punwani,et al. Diagnostic utility of whole body Dixon MRI in multiple myeloma: A multi-reader study , 2017, PloS one.
[9] Evis Sala,et al. Combined Whole Body and Multiparametric Prostate Magnetic Resonance Imaging as a 1‐Step Approach to the Simultaneous Assessment of Local Recurrence and Metastatic Disease after Radical Prostatectomy , 2017, The Journal of urology.
[10] S. Rawal,et al. A Comparative Study of 68Gallium-Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography and Magnetic Resonance Imaging for Lymph Node Staging in High Risk Prostate Cancer Patients: An Initial Experience , 2017, World journal of nuclear medicine.
[11] Stuart A. Taylor,et al. Whole-body MRI quantitative biomarkers are associated significantly with treatment response in patients with newly diagnosed symptomatic multiple myeloma following bortezomib induction , 2017, European Radiology.
[12] A. Kural,et al. The accuracy of 68Ga-PSMA PET/CT in primary lymph node staging in high-risk prostate cancer , 2017, European Journal of Nuclear Medicine and Molecular Imaging.
[13] A. Padhani,et al. The addition of whole-body magnetic resonance imaging to body computerised tomography alters treatment decisions in patients with metastatic breast cancer. , 2017, European journal of cancer.
[14] J. Kuijer,et al. Diffusion-weighted (DW) MRI in lung cancers: ADC test-retest repeatability , 2017, European Radiology.
[15] M. Galia,et al. Whole‐body MRI, FDG‐PET/CT, and bone marrow biopsy, for the assessment of bone marrow involvement in patients with newly diagnosed lymphoma , 2017, Journal of magnetic resonance imaging : JMRI.
[16] D. Collins,et al. Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study. , 2017, Radiology.
[17] H. G. van der Poel,et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. , 2017, European urology.
[18] E. Rummeny,et al. 11C-choline PET/CT and whole-body MRI including diffusion-weighted imaging for patients with recurrent prostate cancer , 2017, Oncotarget.
[19] E. Sala,et al. METastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer , 2017, European urology.
[20] J. Sörensen,et al. Whole-body MRI including diffusion-weighted MRI compared with 5-HTP PET/CT in the detection of neuroendocrine tumors , 2016, Upsala journal of medical sciences.
[21] G. Karanikas,et al. Can Interim 18F-FDG PET or Diffusion-Weighted MRI Predict End-of-Treatment Outcome in FDG-Avid MALT Lymphoma After Rituximab-Based Therapy?: A Preliminary Study in 15 Patients , 2016, Clinical nuclear medicine.
[22] M. Sokolska,et al. Whole body magnetic resonance imaging in newly diagnosed multiple myeloma: early changes in lesional signal fat fraction predict disease response , 2016, British journal of haematology.
[23] Henry Knipe,et al. Oligometastases , 2016, Radiopaedia.org.
[24] A. Bharatha,et al. Association Between MRI Exposure During Pregnancy and Fetal and Childhood Outcomes. , 2016, Journal of the American Medical Association (JAMA).
[25] P. Choyke,et al. Prostate cancer: Birth of a standard: MET-RADS-P for metastatic prostate cancer , 2016, Nature Reviews Urology.
[26] N. Michoux,et al. Whole body MRI (WB‐MRI) assessment of metastatic spread in prostate cancer: Therapeutic perspectives on targeted management of oligometastatic disease , 2016, The Prostate.
[27] R. Kianmanesh,et al. Impact of Liver and Whole-Body Diffusion-Weighted MRI for Neuroendocrine Tumors on Patient Management: A Pilot Study , 2016, Neuroendocrinology.
[28] D. Collins,et al. Inter- and Intra-Observer Repeatability of Quantitative Whole-Body, Diffusion-Weighted Imaging (WBDWI) in Metastatic Bone Disease , 2016, PloS one.
[29] F. Lecouvet. Whole-Body MR Imaging: Musculoskeletal Applications. , 2016, Radiology.
[30] D. Moses,et al. Magnetic resonance imaging in lung: a review of its potential for radiotherapy. , 2016, The British journal of radiology.
[31] R. Braun,et al. The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanoma. , 2016, Swiss medical weekly.
[32] Boudewijn P. F. Lelieveldt,et al. Inter‐station intensity standardization for whole‐body MR data , 2016, Magnetic resonance in medicine.
[33] P. Choyke,et al. Combined Biparametric Prostate Magnetic Resonance Imaging and Prostate-specific Antigen in the Detection of Prostate Cancer: A Validation Study in a Biopsy-naive Patient Population. , 2016, Urology.
[34] D. Collins,et al. Volume of Bone Metastasis Assessed with Whole-Body Diffusion-weighted Imaging Is Associated with Overall Survival in Metastatic Castration-resistant Prostate Cancer. , 2016, Radiology.
[35] S. Fanti,et al. Reply to the letter to the editor 'management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015' by Gillessen et al. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[36] K. Nichols,et al. Diagnostic Performance of Whole-Body MRI as a Tool for Cancer Screening in Children With Genetic Cancer-Predisposing Conditions. , 2015, AJR. American journal of roentgenology.
[37] D. Tárnoki,et al. MR Diagnosis of Bone Metastases at 1.5 T and 3 T: Can STIR Imaging Be Omitted? , 2015, Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren.
[38] H. Ahlström,et al. Whole body MRI, including diffusion-weighted imaging in follow-up of patients with testicular cancer , 2015, Acta oncologica.
[39] M. Roach,et al. Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. , 2015, European urology.
[40] N. Michoux,et al. wbMRI to detect bone metastases: critical review on diagnostic accuracy and comparison to other imaging modalities , 2015, Clinical and Translational Imaging.
[41] N. Michoux,et al. Whole-body 3D T1-weighted MR imaging in patients with prostate cancer: feasibility and evaluation in screening for metastatic disease. , 2015, Radiology.
[42] Y. Akiyama,et al. Iterative Decomposition of Water and Fat with Echo Asymmetry and Least-Squares Estimation (IDEAL) Magnetic Resonance Imaging as a Biomarker for Symptomatic Multiple Myeloma , 2015, PloS one.
[43] Jian Hou,et al. Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] T. Holland-Letz,et al. The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[45] Yan Liu,et al. Monitoring the response of bone metastases to treatment with Magnetic Resonance Imaging and nuclear medicine techniques: a review and position statement by the European Organisation for Research and Treatment of Cancer imaging group. , 2014, European journal of cancer.
[46] G. Corradi,et al. 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-Octreotide SPECT/CT, and Whole-Body MR Imaging in Detection of Neuroendocrine Tumors: A Prospective Trial , 2014, The Journal of Nuclear Medicine.
[47] E. Lis,et al. Whole‐body magnetic resonance imaging (WB‐MRI) as surveillance for subsequent malignancies in survivors of hereditary retinoblastoma: A pilot study , 2014, Pediatric blood & cancer.
[48] M. Kersten,et al. Potential prognostic implications of whole‐body bone marrow MRI in diffuse large B‐cell lymphoma patients with a negative blind bone marrow biopsy , 2014, Journal of magnetic resonance imaging : JMRI.
[49] A. Shaaban,et al. Role of rapid sequence whole-body MRI screening in SDH-associated hereditary paraganglioma families , 2014, Familial Cancer.
[50] Z. Jia,et al. Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis , 2014, Skeletal Radiology.
[51] Laurence Collette,et al. One‐step TNM staging of high‐risk prostate cancer using magnetic resonance imaging (MRI): Toward an upfront simplified “all‐in‐one” imaging approach? , 2014, The Prostate.
[52] D. Collins,et al. Assessment of Treatment Response by Total Tumor Volume and Global Apparent Diffusion Coefficient Using Diffusion-Weighted MRI in Patients with Metastatic Bone Disease: A Feasibility Study , 2014, PloS one.
[53] T. Holland-Letz,et al. Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer , 2013, European Journal of Nuclear Medicine and Molecular Imaging.
[54] M. Weichenthal,et al. Malignant Melanoma S3‐Guideline “Diagnosis, Therapy and Follow‐up of Melanoma” , 2013, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.
[55] P. Summers,et al. Whole-body diffusion-weighted imaging: is it all we need for detecting metastases in melanoma patients? , 2013, European Radiology.
[56] M. Roethke,et al. PET/MRI with a 68Ga-PSMA ligand for the detection of prostate cancer , 2013, European Journal of Nuclear Medicine and Molecular Imaging.
[57] B. Tombal,et al. Novel imaging techniques reshape the landscape in high-risk prostate cancers , 2013, Current opinion in urology.
[58] Jingfei Ma,et al. Conspicuity of bone metastases on fast Dixon-based multisequence whole-body MRI: clinical utility per sequence. , 2013, Magnetic resonance imaging.
[59] Steve Halligan,et al. Diffusion-weighted MRI of lymphoma: prognostic utility and implications for PET/MRI? , 2013, European Journal of Nuclear Medicine and Molecular Imaging.
[60] G. Morgan,et al. Assessing response of myeloma bone disease with diffusion-weighted MRI. , 2012, The British journal of radiology.
[61] J. Sörensen,et al. Whole-body diffusion-weighted MRI compared with (18)F-NaF PET/CT for detection of bone metastases in patients with high-risk prostate carcinoma. , 2012, AJR. American journal of roentgenology.
[62] D. Collins,et al. Whole-body diffusion-weighted MRI: tips, tricks, and pitfalls. , 2012, AJR. American journal of roentgenology.
[63] Ronald M. Summers,et al. Machine learning and radiology , 2012, Medical Image Anal..
[64] M. Puderbach,et al. MRI of the lung (1/3): methods , 2012, Insights into Imaging.
[65] T. Derlin,et al. Diagnostic performance of whole-body MRI for the detection of persistent or relapsing disease in multiple myeloma after stem cell transplantation , 2012, European Radiology.
[66] M. Reiser,et al. FDG-PET-CT and whole-body MRI for triage in patients planned for radioembolisation therapy. , 2012, European journal of radiology.
[67] M. Puderbach,et al. MRI of the lung (2/3). Why … when … how? , 2012, Insights into Imaging.
[68] Jingfei Ma,et al. Fast dixon whole‐body MRI for detecting distant cancer metastasis: a preliminary clinical study , 2012, Journal of magnetic resonance imaging : JMRI.
[69] M. Puderbach,et al. MRI of the lung (3/3)—current applications and future perspectives , 2012, Insights into Imaging.
[70] B. Tombal,et al. Modern Detection of Prostate Cancer's Bone Metastasis: Is the Bone Scan Era Over? , 2011, Advances in urology.
[71] C. Meyer,et al. Diffusion coefficient measurement using a temperature‐controlled fluid for quality control in multicenter studies , 2011, Journal of magnetic resonance imaging : JMRI.
[72] D. Collins,et al. Assessing response in bone metastases in prostate cancer with diffusion weighted MRI , 2011, European Radiology.
[73] M. Forsting,et al. "One-stop-shop" staging: should we prefer FDG-PET/CT or MRI for the detection of bone metastases? , 2011, European journal of radiology.
[74] M. Fenchel,et al. Whole-body diffusion-weighted MRI with apparent diffusion coefficient mapping for early response monitoring in multiple myeloma: preliminary results. , 2011, AJR. American journal of roentgenology.
[75] J. Beyene,et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. , 2011, The Lancet. Oncology.
[76] D. Collins,et al. Optimising diffusion weighted MRI for imaging metastatic and myeloma bone disease and assessing reproducibility , 2011, European Radiology.
[77] Dominik Weishaupt,et al. Diagnostic accuracy of whole-body MRI/DWI image fusion for detection of malignant tumours: a comparison with PET/CT , 2011, European Radiology.
[78] P. Babyn,et al. Imaging of cancer predisposition syndromes in children. , 2011, Radiographics : a review publication of the Radiological Society of North America, Inc.
[79] C. Barceló-Vidal,et al. Comparative study of whole-body MRI and bone scintigraphy for the detection of bone metastases. , 2010, Clinical radiology.
[80] Peter Boesiger,et al. Bone metastases from prostate cancer: assessing treatment response by using diffusion-weighted imaging and functional diffusion maps--initial observations. , 2010, Radiology.
[81] J. Hardes,et al. Advantages in vascular tumors. , 2010, Deutsches Ärzteblatt International.
[82] J. Felblinger,et al. omparative study of two whole-body imaging techniques in the case of elanoma metastases : Advantages of multi-contrast MRI examination ncluding a diffusion-weighted sequence in comparison with PET-CT , 2010 .
[83] Håkan Ahlström,et al. Three‐point dixon method enables whole‐body water and fat imaging of obese subjects , 2010, Magnetic resonance in medicine.
[84] R. Kluge,et al. Whole-body MRI for primary evaluation of malignant disease in children. , 2010, European journal of radiology.
[85] C. Binkert,et al. Comparison of diffusion-weighted whole body MRI and skeletal scintigraphy for the detection of bone metastases in patients with prostate or breast carcinoma , 2010, Skeletal Radiology.
[86] Marion de Jong,et al. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. , 2010, Endocrine-related cancer.
[87] H. Amthauer,et al. Impact of Multiphase 68Ga-DOTATOC-PET/CT on Therapy Management in Patients with Neuroendocrine Tumors , 2009, Neuroendocrinology.
[88] H. Kauczor,et al. Multiple myeloma and monoclonal gammopathy of undetermined significance: importance of whole-body versus spinal MR imaging. , 2009, Radiology.
[89] Jingfei Ma,et al. Fast dixon‐based multisequence and multiplanar MRI for whole‐body detection of cancer metastases , 2009, Journal of magnetic resonance imaging : JMRI.
[90] S. Eustace,et al. Whole-Body MRI versus PET in assessment of multiple myeloma disease activity. , 2009, AJR. American journal of roentgenology.
[91] D. Dearnaley,et al. Prospective assessment of MRI for imaging retroperitoneal metastases from testicular germ cell tumours. , 2009, Clinical radiology.
[92] S. Eustace,et al. Accuracy of whole-body low-dose multidetector CT (WBLDCT) versus skeletal survey in the detection of myelomatous lesions, and correlation of disease distribution with whole-body MRI (WBMRI) , 2009, Skeletal Radiology.
[93] M. Reiser,et al. Whole-body MRI at 1.5 T and 3 T compared with FDG-PET-CT for the detection of tumour recurrence in patients with colorectal cancer , 2009, European Radiology.
[94] P. Choyke,et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. , 2009, Neoplasia.
[95] D. Dearnaley,et al. Evidence-based pragmatic guidelines for the follow-up of testicular cancer: optimising the detection of relapse , 2008, British Journal of Cancer.
[96] Susan Halabi,et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[97] Y. Ohno,et al. Whole‐body MR imaging vs. FDG‐PET: Comparison of accuracy of M‐stage diagnosis for lung cancer patients , 2007, Journal of magnetic resonance imaging : JMRI.
[98] A. Runz,et al. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[99] E. Winer,et al. Metastatic breast cancer. Recommendations proposal from the European School of Oncology (ESO)-MBC Task Force. , 2007, Breast.
[100] C. Claussen,et al. Prospective comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma. , 2007, European journal of cancer.
[101] D. Yang,et al. Whole-body MRI of Langerhans cell histiocytosis: comparison with radiography and bone scintigraphy , 2006, Pediatric Radiology.
[102] I. Magrath,et al. Bone marrow involvement in young patients with non-Hodgkin's lymphoma: the importance of multiple bone marrow samples for accurate staging. , 2006, Medical and pediatric oncology.
[103] T. Nazeer,et al. Role of fluorine‐18 fluoro‐deoxyglucose positron emission tomography scan in the evaluation and follow‐up of patients with low‐grade lymphomas , 2006, Cancer.
[104] T. Nägele,et al. Prospective comparison of the impact on treatment decisions of whole-body magnetic resonance imaging and computed tomography in patients with metastatic malignant melanoma. , 2006, European journal of cancer.
[105] S. Schoenberg,et al. High-Resolution Whole-Body Magnetic Resonance Image Tumor Staging With the Use of Parallel Imaging Versus Dual-Modality Positron Emission Tomography–Computed Tomography: Experience on a 32-Channel System , 2005, Investigative radiology.
[106] J. Connors,et al. State-of-the-art therapeutics: Hodgkin's lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[107] T. Takahara,et al. Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display. , 2004, Radiation medicine.
[108] W. Heston,et al. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer , 2004, Journal of cellular biochemistry.
[109] J. Debatin,et al. Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. , 2003, JAMA.
[110] A. Alavi,et al. Utility of FDG-PET scanning in lymphoma by WHO classification. , 2003, Blood.
[111] J. Biederer,et al. Simulated pulmonary nodules implanted in a dedicated porcine chest phantom: sensitivity of MR imaging for detection. , 2003, Radiology.
[112] Robin M Heidemann,et al. Generalized autocalibrating partially parallel acquisitions (GRAPPA) , 2002, Magnetic resonance in medicine.
[113] M. Slovak,et al. Diagnostic utility of bilateral bone marrow examination , 2002, Cancer.
[114] F. Algaba,et al. EAU Guidelines on Testicular Cancer , 2001, European Urology.
[115] R. Hustinx,et al. Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL). , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[116] R. Walker,et al. Turbo STIR magnetic resonance imaging as a whole‐body screening tool for metastases in patients with breast carcinoma: Preliminary clinical experience , 2000, Journal of magnetic resonance imaging : JMRI.
[117] E. Melhem,et al. A comparison of whole-body turboSTIR MR imaging and planar 99mTc-methylene diphosphonate scintigraphy in the examination of patients with suspected skeletal metastases. , 1997, AJR. American journal of roentgenology.
[118] J M Pauly,et al. Lung parenchyma: projection reconstruction MR imaging. , 1991, Radiology.
[119] P. Roemer,et al. The NMR phased array , 1990, Magnetic resonance in medicine.
[120] M Tubiana,et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[121] D. Feinberg,et al. Halving MR imaging time by conjugation: demonstration at 3.5 kG. , 1986, Radiology.
[122] W. T. Dixon. Simple proton spectroscopic imaging. , 1984, Radiology.
[123] M Tubiana,et al. Report of the Committee on Hodgkin's Disease Staging Classification. , 1971, Cancer research.
[124] Michael R. Aro,et al. Fat-suppression techniques for 3-T MR imaging of the musculoskeletal system. , 2014, Radiographics : a review publication of the Radiological Society of North America, Inc.
[125] T Hielscher,et al. Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma , 2014, Leukemia.
[126] A. Horwich,et al. [EAU guidelines on testicular cancer: 2011 update. European Association of Urology]. , 2012, Actas urologicas espanolas.
[127] N. deSouza,et al. Diffusion Weighted Magnetic Resonance Imaging of metastatic bone disease: A biomarker for treatment response monitoring. , 2010, Cancer biomarkers : section A of Disease markers.
[128] S. Schoenberg,et al. Comprehensive imaging of tumor recurrence in breast cancer patients using whole-body MRI at 1.5 and 3 T compared to FDG-PET-CT. , 2008, European journal of radiology.
[129] R. Fanin,et al. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. , 2007, Haematologica.
[130] M. Langer,et al. [Whole-body MRI in comparison to skeletal scintigraphy for detection of skeletal metastases in patients with solid tumors]. , 2004, Der Radiologe.
[131] E. Imhoff,et al. Comparison of whole-body MRI with automatic moving table technique and bone scintigraphy for screening for bone metastases in patients with breast cancer , 2004, European Radiology.
[132] O. Tanaka,et al. Clinical and prognostic significance of femoral marrow magnetic resonance imaging in patients with malignant lymphoma. , 1997, Blood.
[133] H. Gralnick,et al. Frequencies and patterns of bone marrow involvement in non‐hodgkin lymphomas: Observations on the value of bilateral biopsies , 1977, American journal of hematology.